BJMO - volume 11, issue 3, may 2017
D. Cortinovis MD, P. Bidoli , S. Cavona , M. I. Abbate , U. Malapelle , S. Capici , C. Maggioni MD, F. Colonese MD
In recent years, considerable advances have been achieved in the treatment of non-small cell lung cancer. The discovery of EGFR mutations and ALK translocations has changed clinical management. However, several mechanisms carrying resistance to EGFR tyrosine kinase inhibitors have been reported, as well as resistance to ALK-targeted drugs.
In this review we will focus on non-small cell lung cancer patients with EGFR mutations and ALK translocations, providing a suggested therapeutic algorithm for treating these patients.
(BELG J MED ONCOL 2017;11(3):110–121)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
